- Report
- October 2024
- 182 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- March 2025
- 194 Pages
Global
From €4706EUR$4,950USD£3,953GBP
- Report
- August 2024
- 142 Pages
Global
From €2851EUR$2,999USD£2,395GBP
- Report
- September 2024
- 179 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- May 2024
- 140 Pages
Global
From €4705EUR$4,949USD£3,952GBP
- Report
- September 2023
- 110 Pages
Global
From €5656EUR$5,950USD£4,752GBP
- Report
- March 2022
- 300 Pages
Global
From €4753EUR$5,000USD£3,993GBP
- Report
- November 2023
- 181 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- April 2023
- 113 Pages
Global
From €4516EUR$4,750USD£3,794GBP
- Report
- January 2024
- 105 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Report
- January 2022
- 83 Pages
Global
From €3200EUR$3,606USD£2,782GBP
The Genitourinary Drug market is a subset of the pharmaceutical industry that focuses on drugs used to treat urological disorders. These drugs are used to treat a variety of conditions, including urinary tract infections, bladder control issues, kidney stones, and prostate enlargement. Genitourinary drugs are also used to treat erectile dysfunction, infertility, and other sexual health issues. These drugs are typically prescribed by urologists and other healthcare professionals.
The Genitourinary Drug market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include Pfizer, Merck, AstraZeneca, Sanofi, and Bayer. Other companies in the market include Allergan, GlaxoSmithKline, Novartis, and Eli Lilly. Show Less Read more
